Rapid Dose Therapeutics Corp. (CSE:DOSE)

Revenue by Segment

Financials in millions CAD. Fiscal year is March - February.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Feb 28, 2025	Feb 29, 2024	Feb 28, 2023	Feb 28, 2022	Feb 28, 2021	Feb 29, 2020	Feb 28, 2019	Feb 28, 2018
Pharmaceuticals	2.09M	1.02M	718.30K	1.75M	755.20K
Pharmaceuticals Growth	104.34%	42.06%	-59.00%	131.98%	644.06%
Total	2.09M	1.02M	718.30K	1.75M	755.20K
Total Growth	104.34%	42.06%	-59.00%	131.98%	644.06%

Revenue by Geography

Financials in millions CAD. Fiscal year is March - February.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Feb 28, 2025	Feb 29, 2024	Feb 28, 2023	Feb 28, 2022	Feb 28, 2021	Feb 29, 2020	Feb 28, 2019	Feb 28, 2018
Canada	2.09M	1.02M	718.30K	1.75M	755.20K
Canada Growth	104.34%	42.06%	-59.00%	131.98%	644.06%
Total	2.09M	1.02M	718.30K	1.75M	755.20K
Total Growth	104.34%	42.06%	-59.00%	131.98%	644.06%

Data Source: S&P Global Market Intelligence Last updated: Feb 28, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 29, 2026

Data Sources Report a data error